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Objectives. This study sought to compare the histologic grades
of rejection in endomyocardial biopsy specimens with the global
estimate of myocardial transplant-related cardiac damage de-
tected by myocardial uptake of monoclonal antimyosin antibodies.
Background. The diagnosis and treatment of acute cardiac
allograft rejection is based on the interpretation of endomyocar-
dial biopsies. Because allograft rejection is a multifocal process
and biopsy is obtained from a small area of the right ventricle,
sampling error may occur. Global assessment of myocardial
damage associated with graft rejection is now possible with the
use of antimyosin scintigraphy. The present study was undertaken
to compare the histologic grades of rejection in endomyocardial
biopsy specimens with the global assessment of transplant-related
myocardial damage detected by antimyosin scintigraphy.
Methods. Biopsies (n 5 395) from 112 patients were indepen-
dently interpreted by three pathologists in a blinded manner
according to the original Stanford four-grade (normal, mild,
moderate and severe) and the current International Society of
Heart and Lung Transplantation (ISHLT) seven-grade (0, 1A, 1B,
2, 3A, 3B and 4) classifications. The results were correlated with
395 antimyosin studies performed at the time of the biopsies. The
heart/lung ratio of antimyosin antibody uptake was used to assess
the severity of myocardial damage.
Results. In the Stanford biopsy grade classification, signifi-
cantly higher antimyosin uptake, indicating increasing degrees of
myocardial damage, were associated with normal (1.78 6 0.26),
mild (1.88 6 0.31) and moderate (1.95 6 0.38) biopsy classifica-
tions for rejection (p < 0.01). In the ISHLT classification,
significant differences were detected only for antimyosin uptake
associated with grades 0 (1.77 6 0.26) and 3A (1.98 6 0.39) but
not for intermediate scores (1A, 1B and 2). In view of the similar
intensity of antibody uptake among the various grades, ISHLT
biopsy scores were regrouped: normal biopsies in grade A; 1A and
1B as grade B; and 2 and 3A as grade C. Antimyosin uptake in
grades A, B and C was 1.78 6 0.26, 1.88 6 0.31, 1.95 6 0.38,
respectively (p < 0.01).
Conclusions. The current ISHLT seven-grade scoring system
does not reflect the progressive severity of myocardial damage
associated with heart transplant rejection. Because myocardial
damage constitutes the basis of treatment for allograft rejection,
there is a need to reevaluate the ISHLT grading system, given its
importance for multicenter trials.
(J Am Coll Cardiol 1998;31:1357–61)
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The diagnosis of cardiac allograft rejection is made by histo-
logic interpretation of endomyocardial biopsies (1–3). Billing-
ham (2) initially established a four-grade system to classify
rejection and provide a basis for treatment. After other grading
schemes were proposed, it became apparent that a universally
accepted classification was necessary in order to meaningfully
compare data from various centers (4). This led to the widely
utilized seven-grade working formulation of the International
Society of Heart and Lung Transplantation (ISHLT) (5).
Allograft rejection is a multifocal process and different
regions of myocardium may simultaneously demonstrate vary-
ing severity of rejection. Because endomyocardial biopsy al-
lows an exploration of only a small right ventricular apical area,
sampling error may result. Only if the biopsy incidentally
samples the focus of most severe rejection is an appropriate
diagnosis of rejection likely to be made. For this reason,
clinical trials for evaluation of rejection therapy based on
endomyocardial biopsy diagnosis may be difficult to interpret
(6–8).
Although in the past it has been difficult to evaluate larger
areas of myocardium, global assessment of the heart for
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myocardial damage is now possible with the use of antimyosin
immunoscintigraphy. Antimyosin antibody specifically binds to
the regions of myocardial damage. The loss of sarcolemmal
integrity in degenerating cardiomyocytes results in exposure of
intracellular myosin to intravenously administered radiola-
beled antimyosin antibodies (9–12). We have recently demon-
strated the feasibility of indium-111 antimyosin scintigraphy
for the detection of diffuse myocardial necrosis associated with
heart transplant rejection (13–15). The intensity of antimyosin
antibody uptake reflects the severity of acute rejection de-
tected by biopsy (15). The present study was undertaken to
compare the histologic grades of rejection in endomyocardial
biopsy specimens with the global estimate of transplant-related
myocardial damage detected by antimyosin scintigraphy. Bi-
opsy interpretation was based on the original Stanford (2) and
the currently accepted ISHLT (5) classifications.
Methods
A total of 395 biopsies from 112 patients who had received
a heart transplantation at Hospital Santa Creu i Sant Pau,
Barcelona, were retrospectively and independently interpreted
by three experienced pathologists (referred to as X, Y and Z)
in a blinded fashion. The results were correlated with antimyo-
sin antibody studies concomitantly performed with the biop-
sies.
Interpretation of endomyocardial biopsies, diagnosis of
graft rejection and interobserver variation. Multiple hema-
toxylin-eosin–stained sections of biopsies were reviewed and
graded using both the original Stanford (2) and the currently
accepted ISHLT (5) classifications for allograft rejection (Ap-
pendix 1). Independent interpretation of the biopsies by the
three pathologists was used to assess interobserver variability.
Discrepancies in interpretation between each pair of observers
were classified as major when there was disagreement regard-
ing the presence of myocardial damage, such as mild versus
moderate rejection in the Stanford classification or grades 1A
and 1B versus grades 2, 3A, 3B and 4 in the ISHLT classifica-
tion. The discrepancy was considered minor when there was a
lack of concordance in interpretation of a normal biopsy versus
one showing a myocardial infiltrate without myocyte damage.
The presence of focal endomyocardial infiltrates of lympho-
cytes (Quilty effect) was also assessed and classified as type A
or B. A Quilty type A lesion is neatly localized to the
endocardium; a type B lesion extends into the underlying
myocardium and may be associated with myocardial damage
(5,16,17). The discrepancy in the interpretation of various
biopsy specimens was resolved by the consensus judgment of
all three pathologists and the resulting scores of both classifi-
cations compared with the intensity of antimyosin uptake.
Antimyosin scintigraphic studies. Antimyosin studies were
performed by injecting patients with 500 mg of monoclonal
antimyosin Fab fragment (R11D10) coupled to DTPA labeled
with 2 mCi of indium-111. The radiolabeled antibodies were
injected intravenously and the planar images acquired in
anterior and left anterior oblique projections 48 h later (18).
Antibody uptake was assessed by a heart/lung ratio (HLR),
calculated by dividing the average counts per pixel in a cardiac
region of interest by the average counts in a pulmonary region
of interest in the anterior view. In healthy persons the mean
HLR is 1.39, and 1.55 (mean value plus 2 SD) is used as a
cutpoint to discriminate between normal and abnormal stud-
ies. In transplant recipients HLR , 1.55 is associated with a
virtually nil probability of detecting rejection by biopsy,
whereas an HLR . 1.55 is associated with histologically
verified rejection. In addition, a correlation between the
intensity of uptake and the probability for detecting rejection
at biopsy has been reported (15,18).
Statistical analysis. Analysis of variance was used to com-
pare the mean intensity of antimyosin uptake (HLR) for the
biopsy scores of each classification. When analysis of variance
was statistically significant, comparison of pairs of mean values
was performed using Tukey’s correction for multiple compar-
isons. Chance-corrected agreement among the three indepen-
dent observers (X, Y and Z) was assessed with the kappa
statistic. A kappa score of 0 represents agreement by chance;
the value of 1 reflects perfect agreement (19).
Results
Three hundred ninety-five biopsies were reviewed and the
results correlated with 395 antimyosin scans (Table 1). Of the
395 scans, 339 were performed in the first year after heart
transplantation (72 in the first month, 168 in months 2 to 3, 50
Abbreviations and Acronyms
HLR 5 Heart/lung ratio of antimyosin uptake
ISHLT 5 International Society of Heart and Lung Transplantation
Table 1. Correlation of Transplant Rejection Detected by
Endomyocardial Biopsy and Antimyosin Scan
Classification
No. of
Biopsies
HLR
(mean 6 SD)
Stanford* 395 1.81 6 0.29
Normal 281 1.78 6 0.26
Mild 84 1.88 6 0.31
Moderate 30 1.95 6 0.38
Severe 0 0
ISHLT† 395 1.81 6 0.29
Grade 0 273 1.77 6 0.26
Grade 1A 48 1.88 6 0.31
Grade 1B 37 1.84 6 0.25
Grade 2 11 1.97 6 0.37
Grade 3A 26 1.98 6 0.39
Grade 3B 0 0
Grade 4 0 0
*Billingham (2). †Billingham et al. (5). HLR 5 heart/lung ratio of antimyo-
sin uptake; ISHLT 5 International Society of Heart and Lung Transplantation.
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in 4 to 6, and 49 in months 7 to 12). Fifty-six studies were
performed after the first year of heart transplantation. The
median interval between biopsies and antimyosin scans was 2
days.
Interobserver variability in biopsy interpretation. The in-
terobserver variability of biopsy interpretation for the two
classifications is shown in Table 2. No statistically significant
differences were observed between any pair of observers or
between observations based on the two classifications. The
chance-corrected agreement among the observers for the
Stanford and ISHLT grading systems was 0.39 and 0.34,
respectively. The proportion of major disagreement in 395
biopsy specimens based on the two classifications ranged from
7% to 17%. Minor discrepancies were observed in 15% to 20%
of the biopsy specimens.
Intensity of antimyosin uptake and histologic grades of
rejection. Using the original Stanford classification, 281 biop-
sies were graded as normal; mild graft rejection was detected
in 84 specimens and moderate in 30; none of the biopsies were
classified as severe (Table 1, Fig. 1). The intensity of antimyo-
sin antibody uptake represented by the HLR was 1.78 6 0.26,
1.88 6 0.31 and 1.95 6 0.38 in biopsy specimens graded as
normal, mild and moderate graft rejection, respectively (Fig.
2A, Table 1). Antimyosin uptake associated with mild and
moderate rejection was significantly higher than with the
normal biopsy specimens (p , 0.01).
Utilizing the ISHLT classification, uptake associated with
grades 0, 1A, 1B, 2 and 3A biopsy specimens was 1.77 6 0.26,
1.88 6 0.31, 1.84 6 0.25, 1.97 6 0.37 and 1.98 6 0.39,
respectively (Table 1, Fig. 2B); none of the biopsies were
classified as grade 3B or 4. No correlation was observed
between antimyosin uptake and increasing severity of rejection
by ISHLT grades (Fig. 2 and 3). The only statistically signifi-
cant difference among various pairs of ISHLT grades was
between grades 0 and 3A (p , 0.01).
In view of the similar intensity of antibody uptake among
the various grades, ISHLT biopsy scores were regrouped:
normal biopsies in grade A; 1A and 1B as grade B; and 2 and
3A as grade C. Antimyosin uptake reflected by HLR in biopsy
grades A, B and C was 1.78 6 0.26, 1.88 6 0.31 and 1.95 6
0.38, respectively (Fig. 2C). Differences between A and B and
between A and C were significant (p , 0.01), and a marginally
significant difference was found between groups B and C (p ,
0.10).
Relation of antimyosin antibody uptake to Quilty effect.
Antimyosin uptake was similar in patients with or without
Quilty lesions, and in those demonstrating Quilty type a or type
B lesions. The HLR of 1.81 6 0.3 in 45 studies associated with
a Quilty type a lesion was similar to that in 20 biopsy specimens
with a Quilty type B effect (1.79 6 0.24; p 5 0.79). No
differences in HLR were observed between the Quilty A effect
(1.81 6 0.30) and the remaining biopsy specimens (1.81 6
0.27). The HLR was also similar in 20 studies coincident with
biopsies showing a Quilty B effect (1.79 6 0.24) compared with
Table 2. Interobserver Variability in Interpretation of
Endomyocardial Biopsy by Three Pathologists (X, Y and Z)
Kappa†
Major Disagreement
(%)*
Minor Disagreement
(%)*
X–Y‡ X–Z Y–Z X–Y X–Z Y–Z
Stanford§ 0.39 7 15 16 15 18 19
ISHLT\ 0.34 12 13 17 12 18 19
*Discrepancies in interpretation between each pair of observers were
classified as major when there was disagreement regarding the presence of
myocardial damage such as mild versus moderate rejection in the Stanford
classification or grades 1A and 1B versus grades 2, 3A, 3B and 4 in the ISHLT
classification. The discrepancy was considered minor when there was a lack of
concordance in interpretation of a normal biopsy versus one showing a myocar-
dial infiltrate without myocyte damage. †Chance-corrected overall agreement
between three observers. ‡Pairs of pathologists interpreting endomyocardial
biopsies. §Billingham (2). \Billingham et al. (5). ISHLT 5 International Society
for Heart and Lung Transplantation.
Figure 1. Antimyosin scans in increasing degrees of transplant rejec-
tion as detected by endomyocardial biopsies. A, Endomyocardial
biopsy from a patient with no histologic evidence of transplant
rejection was reported as normal by the original Stanford classification
and grade 0 by the ISHLT classification. B, Antimyosin scan from the
same patient (anterior view) demonstrates no uptake of antimyosin
antibody in the cardiac region; the antimyosin uptake was 1.46. C,
Endomyocardial biopsy from another patient who demonstrated mild
transplant rejection by the Stanford classification and ISHLT grade 1B
rejection. D, Antimyosin uptake in this patient can be clearly seen in
the cardiac region, which is of mild intensity as reflected by an HLR of
1.65. F, Abnormal antimyosin scan with significant antibody uptake
(HLR 1.98) was associated with moderate (Stanford) or ISHLT grade
3A transplant rejection E, in endomyocardial biopsy.
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those not showing such effect (1.81 6 0.29). Therefore, no
differences were found in the degree of antimyosin uptake of
hearts between those with or without Quilty effect, indicating
that this histologic finding is unrelated to rejection.
Discussion
Cardiac allograft rejection manifests pathologically as in-
terstitial mononuclear infiltration, which leads to an increasing
degree of myocyte necrosis. The pathologic classifications of
allograft rejection are designed to represent the severity of the
immunologic process. The most critical feature of transplant
rejection is myocyte necrosis, which constitutes the indication
for augmentation of immunosuppressive therapy.
The present study utilized radiolabeled antimyosin imaging
to identify the extent of myocardial necrosis in vivo and
correlated it with the biopsy evidence of myocyte necrosis.
Antimyosin scintigraphy allows sensitive identification of myo-
cardial necrosis. After heart transplantation antibody uptake
can be equated with rejection activity: lack of myocardial
uptake is associated with absent rejection activity detected at
biopsy; antibody uptake directly correlates with the presence
and severity of biopsy-proven rejection (14,15). In addition,
very intense uptake is associated with a higher probability of
occurrence of rejection-related complications (15). Therefore,
this technology provides a unique opportunity to semiquanti-
tavely assess the degree of myocardial damage after heart
transplantation, eliminating the inherent limitation of assum-
ing that the histologic changes in a small myocardial region of
the right ventricular apex obtained at biopsy represents the
phenomena occurring in the whole myocardium (20).
Comparison of myocardial antimyosin uptake in the scoring
system suggests that there is a good correlation between
antimyosin uptake and the original Stanford classification (Fig.
1A), but the correlation between increasing grades of histo-
logic rejection in the present ISHLT scoring system and the
intensity of antimyosin uptake is poor (Fig. 1B). However,
Figure 3. Discrepancy in the results of antimyosin scans and histologic
transplant rejection can occasionally be explained by sampling error of
endomyocardial biopsy. Three abnormal antimyosin scans (B, D and F)
of approximately same intensity obtained 1, 2 and 3 months after heart
transplantation from the same patient. HLRs were 1.80, 1.90 and 1.85,
respectively. Endomyocardial biopsies obtained at the time of antimyo-
sin scans demonstrated ISHLT grade 3A, 0 and 3A transplant rejection
(A, C and E). Evidence of significant rejection in the first and third
biopsy but persistent antimyosin uptake suggests that sampling error of
endomyocardial biopsy is a distinct possibility.
Figure 2. Relation between the intensity of antimyosin uptake (rep-
resented by HLR in the ordinate) and the histologic scores for
rejection of three endomyocardial biopsy classifications for acute
cardiac rejection (see Appendix). Results are expressed as the mean
value 6 SD of HLR for each biopsy score. A, Original Stanford
classification: HLRs for biopsies showing normal (n 5 281), mild (n 5
84) or moderate (n 5 30) rejection. B, Current ISHLT biopsy
classification: grades 0 (n 5 273), 1A (n 5 48), 1B (n 5 37), 2 (n 5 11)
and 3A (n 5 26). C, HLRs for recoded ISHLT scores A (n 5 273), B
(n 5 85) and C (n 5 37).
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regrouping intermediate grades of the latter into a three-score
system, similar to the classification proposed initially, corre-
lated well with the discriminate value of the biopsy (Fig. 1C).
The poor results of the ISHLT classification are in keeping
with the experience of 16 pathologists reported by Winters et
al. (21) utilizing the ISHLT classification who found that the
poorest correlation among the group was with grade 2 rejec-
tion and its differentiation from grades 1A and 3A. This
suggests the need to reevaluate the ISHLT grading system
given its importance for multicenter trials.
Conclusions. The current ISHLT seven-grade scoring sys-
tem does not reflect the severity of myocardial damage asso-
ciated with cardiac allograft rejection. A simple biopsy classi-
fication of heart transplant rejection into the categories
“normal,” “infiltration only” and “infiltration with myocyte
necrosis,” appears to better represent the severity of myocar-
dial damage.
Appendix
Endomyocardial Biopsy Classification for Rejection
Stanford (Billingham [2]):
Absent: No rejection
Mild: Focal or diffuse lymphocytic infiltrates without myocyte
damage
Moderate: Focal or diffuse lymphocytic infiltrates with myocyte
damage
Severe: Extensive lymphocytic infiltrates associated with neutro-
phils and interstitial hemorrhage
International Society for Heart and Lung Transplantation (ISHLT)
(Billingham et al. [5]):
0: No rejection
1A: Focal (perivascular or interstitial) lymphocytic infiltrates with-
out necrosis
1B: Diffuse but sparse infiltrate without necrosis
2: One focus only with aggressive infiltration or focal myocyte
damage, or both
3A: Multifocal aggressive infiltrates or myocyte damage, or both
3B: Diffuse inflammatory process with necrosis
4: Diffuse aggressive polymorphous 6 infiltrate 6 edema 6
hemorrhage 6 vasculitis, with necrosis
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